|
gptkbp:instanceOf
|
antineoplastic agent
taxane
nanoparticle formulation
|
|
gptkbp:activeIngredient
|
paclitaxel
|
|
gptkbp:administeredBy
|
infusion
|
|
gptkbp:approvedBy
|
gptkb:FDA
2005
|
|
gptkbp:ATCCode
|
gptkb:L01CD02
|
|
gptkbp:brand
|
gptkb:Abraxane
|
|
gptkbp:contraindication
|
severe neutropenia
|
|
gptkbp:developedTo
|
improve solubility of paclitaxel
reduce hypersensitivity reactions
|
|
gptkbp:eliminationHalfLife
|
27 hours
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:formulationContains
|
albumin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
albumin-bound paclitaxel
|
|
gptkbp:indication
|
gptkb:non-small_cell_lung_cancer
gptkb:cancer
pancreatic cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Celgene
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:mechanismOfAction
|
microtubule stabilization
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:reduces
|
tumor cell proliferation
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
fatigue
alopecia
peripheral neuropathy
neutropenia
|
|
gptkbp:bfsParent
|
gptkb:Abraxane
gptkb:Paclitaxel
|
|
gptkbp:bfsLayer
|
7
|